Soothing Moisturizing Repair Cream is a newly launched emollient with anti-inflammatory, itch-relieving, and moisturizing properties. The purpose of this study is to evaluate the incremental value of Soothing Moisturizing Repair Cream in the efficacy of dupilumab monotherapy for children with severe atopic dermatitis (AD). This study included 36 children with severe AD who completed a 12-week treatment regimen from November 2022 to April 2023. There were 17 children in the experimental group and 19 in the control group. The control group received only dupilumab monotherapy, while the experimental group used Soothing Moisturizing Repair Cream plus dupilumab. Changes in Scoring of AD (SCORAD), AD Control Tool (ADCT), and Numerical Rating Scale (NRS) scores before and after treatment were compared, along with any adverse reactions to soothing moisturizing repairing cream. There were no significant differences in gender, age, disease duration, cumulative dose of dupilumab, SCORAD, ADCT, and NRS scores between the 2 groups before treatment. Both groups showed a gradual decline in SCORAD, ADCT, and NRS scores at 2, 4, 8, and 12 weeks after starting dupilumab treatment, with significant differences between each time point ( P < .05). The experimental group showed further significant reductions in SCORAD, ADCT, and NRS scores compared to the control group at the same time points ( P < .05). Adverse reactions to were generally mild. Our real-life data seems to confirm the Moisturizing Repair Cream significantly enhances the effectiveness of dupilumab monotherapy in treating children with severe AD.
Lin et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: